Literature DB >> 3789837

Postcholecystectomy wound infection. The impact of prophylactic antibiotics on the epidemiology of infections.

R A Garibaldi, D Skolnick, S Maglio, J Graham, T Lerer, R Lyons, D Becker.   

Abstract

The clinical courses of 347 patients undergoing gallbladder surgeries were monitored to study the epidemiology of postcholecystectomy wound infection in a hospital in which high-risk patients received prophylactic antibiotics. Overall, 3.8% of patients had wound infections. Patients who had positive bile cultures taken during surgery or positive intraoperative wound cultures had higher rates of infection than patients with negative cultures. However, there was a poor correlation among the bacterial isolates that were recovered from the bile or the wound surface during surgery and from postoperative infections. Antibiotic-sensitive enteric bacteria were recovered from bile samples at surgery, gram-positive organisms and enteric gram-negative bacteria were isolated from intraoperative cultures of the wound surface, and antibiotic-resistant gram-negative bacteria or enterococci were recovered from wounds that developed postoperative infections. There was a strong association between the prior receipt of prophylactic antibiotics and infections with antibiotic-resistant bacteria. Data suggest that bactibilia is still an important epidemiologic marker that identifies patients at high risk for subsequent wound infection. However, in patients who have received prophylactic antibiotics, intraoperative cultures cannot be relied on to guide the choice of empiric therapeutic antibiotics for postoperative infections. Bacteria responsible for these infections are not identified by cultures taken at the time of surgery and are often resistant to the class of antibiotics used for prophylaxis.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3789837      PMCID: PMC1251420          DOI: 10.1097/00000658-198612000-00006

Source DB:  PubMed          Journal:  Ann Surg        ISSN: 0003-4932            Impact factor:   12.969


  30 in total

1.  BACTERIAL FLORA OF CLEAN WOUNDS AND ITS RELATION TO SUBSEQUENT SEPSIS.

Authors:  C W HOWE
Journal:  Am J Surg       Date:  1964-05       Impact factor: 2.565

2.  Gallbladder bacteriology, histology, and gallstones. Study of unselected cholecystectomy specimens in Honolulu.

Authors:  F H Fukunaga
Journal:  Arch Surg       Date:  1973-02

3.  Preoperative antibiotics in biliary surgery.

Authors:  S H Chetlin; D W Elliott
Journal:  Arch Surg       Date:  1973-08

4.  The significance of infection in biliary disease.

Authors:  C S Haw; A A Gunn
Journal:  J R Coll Surg Edinb       Date:  1973-07

5.  An endogenous source for wound infections based on quantitative bacteriology of the biliary tract.

Authors:  M C Robson; J N Bogart; J P Heggers
Journal:  Surgery       Date:  1970-09       Impact factor: 3.982

6.  Operative wound cultures and wound infections: a study of 342 patients.

Authors:  M L Dillon; R W Postlethwait; K A Bowling
Journal:  Ann Surg       Date:  1969-12       Impact factor: 12.969

7.  Biliary bacteremia.

Authors:  S H Chetlin; D W Elliott
Journal:  Arch Surg       Date:  1971-04

8.  An evaluation of antibiotics in biliary tract surgery.

Authors:  L J Pyrtek; S A Bartus
Journal:  Surg Gynecol Obstet       Date:  1967-07

9.  Multivariate analysis of clinical and operative findings associated with bilary sepsis.

Authors:  M R Keighley; R Flinn; J Alexander-Williams
Journal:  Br J Surg       Date:  1976-07       Impact factor: 6.939

10.  A controlled trial of parenteral prophylactic gentamicin therapy in biliary surgery.

Authors:  M R Keighley; R M Baddeley; D W Burdon; J A Edwards; A H Quoraishi
Journal:  Br J Surg       Date:  1975-04       Impact factor: 6.939

View more
  1 in total

1.  Additional surgical procedure is a risk factor for surgical site infections after laparoscopic cholecystectomy.

Authors:  René Fahrner; Thomas Malinka; Jennifer Klasen; Daniel Candinas; Guido Beldi
Journal:  Langenbecks Arch Surg       Date:  2014-04-23       Impact factor: 3.445

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.